OnePin Peptide Library · Growth Hormone
HGH 191AA (Somatropin)
HGH · Human Growth Hormone · Somatropin · rhGH · Norditropin · Genotropin · Humatrope · Saizen
HGH 191AA refers to recombinant human growth hormone produced via E. coli or mammalian cell expression with the native 191-amino-acid sequence (somatropin). This is the FDA-approved form sold as Genotropin (Pfizer), Humatrope (Eli Lilly), Norditropin (Novo Nordisk), Saizen (Merck-Serono), Omnitrope (Sandoz), and Zomacton (Ferring), among others. Distinguished from older 192AA preparations (somatrem, with an extra N-terminal methionine) and from 'generic' research-grade HGH that may not match the native sequence.
Most users dose at bedtime to mimic endogenous nocturnal GH peak. Reconstitute lyophilized vial with bacteriostatic water - do NOT shake (denatures protein). Inject into thigh or abdominal subcutaneous tissue. Rotate sites. Avoid heavy meals 2 hours pre-dose for full GH/IGF-1 pulse.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Somatropin binds the growth hormone receptor (GHR), a class I cytokine receptor expressed broadly on hepatocytes, adipocytes, chondrocytes, immune cells, and many other tissues. GHR ligation triggers JAK2-STAT5 signaling, with downstream transcriptional activation of IGF-1 and IGFBP-3 (primarily in liver) and direct local effects in target tissues.
Linear Growth (children)
GH-driven hepatic IGF-1 stimulates chondrocyte proliferation in growth plates - the basis of GHD pediatric replacement.
Lipolysis
GHR activation in adipocytes increases hormone-sensitive lipase activity and free fatty acid release - drives fat mass loss particularly in visceral depots.
Anabolic Action
GH-driven IGF-1 increases muscle protein synthesis, satellite cell activation, and lean mass. GH itself has direct anti-catabolic action via insulin-like signaling at high concentrations.
Insulin Antagonism
GH antagonizes insulin action at high levels - clinically relevant only at supraphysiologic doses or in GH excess (acromegaly). Therapeutic doses produce mild glucose excursions; supraphysiologic doses can cause overt insulin resistance.
Bone Density
Chronic GH replacement in adult GHD increases BMD modestly via direct osteoblast and indirect IGF-1 effects.
Connective Tissue
GH/IGF-1 stimulates collagen synthesis - basis of off-label injury-recovery use, though human data limited to GHD populations.
What to expect
Week 1-2: water retention, joint stiffness, possible mild edema. IGF-1 begins rising. Subjective sleep changes possible.
Week 4-12: peak body composition response - reduced visceral fat, modest lean mass gain. Improved exercise recovery anecdotally.
Month 3-6 and beyond: sustained body composition with continued daily dosing. Long-term safety in non-FDA-approved populations not established.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Water retention, edema (face, hands, ankles)
- Joint pain and stiffness
- Carpal tunnel syndrome symptoms (wrist tingling)
- Mild hyperglycemia / impaired fasting glucose
- Injection site reaction
- Headache
- Vivid dreams
Less common & notes
- Insulin resistance progressing to overt type 2 diabetes at supraphysiologic doses.
- Acromegaly-like features (jaw growth, brow ridge prominence, hand/foot enlargement) at chronic supraphysiologic exposure.
- Unmasking of subclinical hypothyroidism (GH suppresses T4-to-T3 conversion).
- Theoretical malignancy promotion via IGF-1 mitogenic action - acromegaly epidemiology suggests modestly increased colon cancer risk.
- Rare benign intracranial hypertension (pseudotumor cerebri) - new headache + visual changes warrants immediate workup.
- Slipped capital femoral epiphysis in pediatric patients with predisposing factors.
- Allergic reaction to formulation rare.
- Long-term cardiovascular outcomes in healthy adults using off-label GH not characterized.
Pharmacokinetics
Storage. Lyophilized vial: refrigerate (2-8°C / 36-46°F). Do NOT freeze - freezing denatures the protein. Light-sensitive. After reconstitution with bacteriostatic water: refrigerate, use within 14-28 days per manufacturer label. Do NOT shake during reconstitution - swirl gently to dissolve. Discard if cloudy, discolored, or contains particulates. Pen devices have specific post-loading expiration windows - check manufacturer instructions.
Regulatory status
FDA-approved as Genotropin (Pfizer), Humatrope (Eli Lilly), Norditropin (Novo Nordisk), Saizen (Merck-Serono), Omnitrope (Sandoz), Zomacton (Ferring), Serostim (HIV wasting). All require prescription. Distribution for non-FDA-approved indications is restricted by 21 USC 333(e) - federal criminal statute making distribution of HGH for non-approved use a felony. Prohibited by WADA in class S2 both in and out of competition. Sale of research-grade HGH for human use is illegal in the United States; the 'research chemical' framing common for other peptides does NOT apply to HGH 191AA which is uniquely federally restricted.
Put it to work
Calculate, log & track
Open HGH 191AA (Somatropin) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open HGH 191AA (Somatropin) in the app →Go deeper
The guide & community
The complete HGH 191AA (Somatropin) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗